Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases, has announced its plans to release second quarter 2024 financial results on Wednesday, July 31, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results and provide updates on recent corporate developments.

Interested parties can register for the conference call through a provided link, which will give them dial-in details and a unique PIN for access. An audio webcast will also be available through the company's Investor Relations section on their website.

CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its second quarter 2024 financial results will be released on Wednesday, July 31, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

FAQ

When will Fulcrum Therapeutics (FULC) release its Q2 2024 financial results?

Fulcrum Therapeutics (FULC) will release its second quarter 2024 financial results on Wednesday, July 31, 2024, before the U.S. financial markets open.

What time is Fulcrum Therapeutics' (FULC) Q2 2024 earnings call scheduled for?

Fulcrum Therapeutics' (FULC) Q2 2024 earnings call is scheduled for Wednesday, July 31, 2024, at 8:00 a.m. ET.

How can investors access Fulcrum Therapeutics' (FULC) Q2 2024 earnings call?

Investors can access Fulcrum Therapeutics' (FULC) Q2 2024 earnings call by registering through a provided link to receive dial-in details and a unique PIN. An audio webcast will also be available on the company's website.

What is Fulcrum Therapeutics' (FULC) primary focus as a company?

Fulcrum Therapeutics (FULC) is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases.